Last reviewed · How we verify
Ketamine IV Infusion
At a glance
| Generic name | Ketamine IV Infusion |
|---|---|
| Also known as | Ketalar, Ketamine |
| Sponsor | Alameda Health System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
- InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (PHASE3)
- Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults (PHASE2)
- Postoperative Pain Monitoring With ANI in Lumbar Spine Surgery (NA)
- ACT_for Alcohol Use Disorder and Depression (NA)
- An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium (PHASE4)
- Ketamine Administration for Postoperative Pain Management in Patients Undergoing Knee Arthroplasty (NA)
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine IV Infusion CI brief — competitive landscape report
- Ketamine IV Infusion updates RSS · CI watch RSS
- Alameda Health System portfolio CI